{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:38:31Z","timestamp":1786984711138,"version":"build-2736575974"},"reference-count":213,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Applied Radiation and Isotopes"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.apradiso.2024.111527","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:15:49Z","timestamp":1727180149000},"page":"111527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Adverse reactions to therapeutic radiopharmaceuticals"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5291-810X","authenticated-orcid":false,"given":"Mine","family":"Silindir-Gunay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Ozolmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apradiso.2024.111527_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00259-014-2862-z","article-title":"177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study","volume":"42","author":"Agarwal","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.apradiso.2024.111527_bib2","series-title":"Patients Selection for Radiosynovectomy. IAEA Radioisotopes and Radiopharmaceuticals Reports No.3 Production, Quality Control and Clinical Applications of Radiosynovectomy Agents","author":"Agency","year":"2021"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-015-0114-2","article-title":"Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study","volume":"5","author":"Ahmadzadehfar","year":"2015","journal-title":"EJNMMI Res."},{"issue":"11","key":"10.1016\/j.apradiso.2024.111527_bib4","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","author":"Ahmadzadehfar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.apradiso.2024.111527_bib5","article-title":"Astatine-211 based radionuclide therapy: current clinical trial landscape","volume":"9","author":"Albertsson","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib6","series-title":"Therapeutic Nuclear Medicine","first-page":"495","article-title":"Radionuclide therapy for bleeding joints in Hemophilia","author":"Andres-Barrenechea","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies","volume":"32","author":"Anthony","year":"2002","journal-title":"Semin. Nucl. Med. Elsevier"},{"key":"10.1016\/j.apradiso.2024.111527_bib8","series-title":"Radioembolization: Concepts and Procedures. Therapeutic Nuclear Medicine","first-page":"361","author":"Arbizu","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib9","series-title":"Nuclear Medicine Therapy: Side Effects and Complications","first-page":"113","article-title":"Radioimmunotherapy of lymphomas","author":"Bailly","year":"2019"},{"issue":"Suppl. 1","key":"10.1016\/j.apradiso.2024.111527_bib10","first-page":"462","article-title":"Clinical experience on 225Ac-PSMA-617 targeted alpha therapy in metastatic castration resistant prostate cancer patients: safety and efficacy results","volume":"60","author":"Bal","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib11","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"365","article-title":"Targeted therapy with radium-223 of bone metastases","author":"Baldari","year":"2018"},{"key":"10.1016\/j.apradiso.2024.111527_bib12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2967\/jnumed.122.264043","article-title":"Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE\u2013targeted \u03b1-therapy and capecitabine: a real-world-scenario management-based long-term outcome study","volume":"64","author":"Ballal","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib14","series-title":"Cyclotron-Based Radiopharmaceuticals for Nuclear Medicine Therapy. Therapeutic Nuclear Medicine","first-page":"95","author":"Barbet","year":"2014"},{"issue":"1 Suppl. l","key":"10.1016\/j.apradiso.2024.111527_bib15","first-page":"99","article-title":"Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose\u2013effect relationship","volume":"46","author":"Barone","year":"2005","journal-title":"Journal of nuclear medicine"},{"key":"10.1016\/j.apradiso.2024.111527_bib16","series-title":"Therapeutic Nuclear Medicine","first-page":"583","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors expressing somatostatin receptors","author":"Baum","year":"2014"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43429-8","article-title":"Preclinical evaluation of [58mCo]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer","volume":"13","author":"Baun","year":"2023","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.anplas.2017.11.007","article-title":"Complex upper arm reconstruction using an antero-lateral thigh free flap after an extravasation of Yttrium-90-ibritumomab Tiuxetan: a case report and literature review","volume":"63","author":"Baus","year":"2018","journal-title":"Annales de Chirurgie Plastique Esth\u00e9tique"},{"issue":"12","key":"10.1016\/j.apradiso.2024.111527_bib19","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib20","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ijrobp.2007.05.009","article-title":"Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-Sponsored Multination study","volume":"69","author":"Bernal","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jvir.2016.01.147","article-title":"Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres","volume":"27","author":"Biederman","year":"2016","journal-title":"J Vasc Interv Radiol"},{"issue":"Suppl. 4","key":"10.1016\/j.apradiso.2024.111527_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/10428140310001616935","article-title":"The role of nuclear medicine in the treatment of non-hodgkin's lymphoma (NHL)","volume":"44","author":"Bischof Delaloye","year":"2003","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.apradiso.2024.111527_bib23","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00259-013-2510-z","article-title":"Toxicity of upfront 1\u00b31I-metaiodobenzylguanidine (1\u00b31I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis","volume":"40","author":"Bleeker","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.apradiso.2024.111527_bib24","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s00259-004-1571-4","article-title":"Receptor radionuclide therapy with 90Y-[DOTA] 0-Tyr 3-octreotide (90Y-DOTATOC) in neuroendocrine tumours","volume":"31","author":"Bodei","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.apradiso.2024.111527_bib25","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"107","article-title":"Medical devices for radioembolization","author":"Bogni","year":"2018"},{"issue":"1, Suppl. ment","key":"10.1016\/j.apradiso.2024.111527_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2003.11.002","article-title":"Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)","volume":"34","author":"Borghaei","year":"2004","journal-title":"Semin. Nucl. Med."},{"issue":"7","key":"10.1016\/j.apradiso.2024.111527_bib27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/01.mnm.0000130241.22068.45","article-title":"A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma","volume":"25","author":"Boschi","year":"2004","journal-title":"Nucl. Med. Commun."},{"issue":"4","key":"10.1016\/j.apradiso.2024.111527_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semnuclmed.2016.01.008","article-title":"Intra-arterial radionuclide therapies for liver tumors","volume":"46","author":"Bozkurt","year":"2016","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib29","series-title":"Therapeutic Nuclear Medicine","first-page":"447","article-title":"Treatment of osteoblastic skeletal metastases by the alpha-emitting bone-seeker radium-223","author":"Bruland","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib30","series-title":"Therapeutic Nuclear Medicine","first-page":"433","article-title":"Radionuclide therapy of bone metastases using rhenium-188 hydroxyethylidene diphosphonate","author":"Bucerius","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib31","series-title":"Therapeutic Nuclear Medicine","first-page":"669","article-title":"Myeloablative radioimmunotherapy in conditioning of acute leukemia, MDS, and multiple myeloma prior to hematological stem cell transplantation","author":"Buchmann","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib32","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00259-003-1197-y","article-title":"A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer","volume":"30","author":"Buffa","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.apradiso.2024.111527_bib33","series-title":"Nuclear Medicine Therapy: Side Effects and Complications","first-page":"11","article-title":"Radioiodine therapy of benign thyroid diseases","author":"Campenn\u00ec","year":"2019"},{"issue":"S2","key":"10.1016\/j.apradiso.2024.111527_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/lt.20036","article-title":"Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients","volume":"10","author":"Carr","year":"2004","journal-title":"Liver Transplant."},{"key":"10.1016\/j.apradiso.2024.111527_bib35","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"253","article-title":"Treatment with 131I-mIBG (metaiodobenzylguanidine): indications, procedures, and results","author":"Castellani","year":"2018"},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib36","first-page":"237","article-title":"The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases","volume":"26","author":"Cheng","year":"2011","journal-title":"Cancer Biother. Rad."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib37","first-page":"503","article-title":"A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres","volume":"56","author":"Chiesa","year":"2012","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/snuc.2002.31563","article-title":"Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: the experience of the European Institute of oncology group","volume":"32","author":"Chinol","year":"2002","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib39","series-title":"Therapeutic Nuclear Medicine","first-page":"225","article-title":"Sodium iodide symporter in thyroid carcinoma","author":"Chung","year":"2014"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1210\/jc.2013-3595","article-title":"Primary ovarian insufficiency in children after treatment with 131I-metaiodobenzylguanidine for neuroblastoma: report of the first two cases","volume":"99","author":"Clement","year":"2014","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib41","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00259-014-2967-4","article-title":"Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma","volume":"42","author":"Clement","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"3","key":"10.1016\/j.apradiso.2024.111527_bib42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2007.03.056","article-title":"Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer","volume":"69","author":"Coldwell","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.apradiso.2024.111527_bib43","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00003072-200007000-00002","article-title":"Permanent iatrogenic vocal cord paralysis after I-131 therapy: a case report and literature review","volume":"25","author":"Coover","year":"2000","journal-title":"Clin. Nucl. Med."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib44","first-page":"550","article-title":"Adverse reactions to radiopharmaceuticals","volume":"23","author":"Cordova","year":"1982","journal-title":"J. Nucl. Med."},{"issue":"15 Suppl. l","key":"10.1016\/j.apradiso.2024.111527_bib45","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1200\/jco.2008.26.15_suppl.4078","article-title":"Clinical safety and efficacy of 90yttrium resin microspheres alone in unresectable, heavily pre-treated colorectal liver metastases: results of a phase II trial","volume":"26","author":"Cosimelli","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.apradiso.2024.111527_bib46","series-title":"Therapeutic Nuclear Medicine","first-page":"769","article-title":"Dosimetry for peptide receptor radionuclide therapy","author":"Cremonesi","year":"2014"},{"issue":"4","key":"10.1016\/j.apradiso.2024.111527_bib47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","article-title":"Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study","volume":"21","author":"Cwikla","year":"2010","journal-title":"Ann. Oncol."},{"issue":"27","key":"10.1016\/j.apradiso.2024.111527_bib48","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib49","first-page":"1673","article-title":"Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres","volume":"41","author":"Dancey","year":"2000","journal-title":"Journal of nuclear medicine"},{"key":"10.1016\/j.apradiso.2024.111527_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10585-016-9831-9","article-title":"Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons","volume":"34","author":"Das","year":"2017","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/ard.34.1.62","article-title":"Acute knee joint rupture after yttrium 90 injection","volume":"34","author":"Davis","year":"1975","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib52","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/BF00181067","article-title":"Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer","volume":"21","author":"de Klerk","year":"1994","journal-title":"Eur. J. Nucl. Med."},{"issue":"4B","key":"10.1016\/j.apradiso.2024.111527_bib53","first-page":"2779","article-title":"Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study","volume":"18","author":"DeNardo","year":"1998","journal-title":"Anticancer Res."},{"key":"10.1016\/j.apradiso.2024.111527_bib54","series-title":"Therapeutic Nuclear Medicine","first-page":"335","article-title":"Radioiodine therapy of hyperthyroidism (toxic goiter, hyperfunctioning nodule) and non-toxic goiter: procedures and guidelines","author":"Dietlein","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib55","first-page":"S653","article-title":"No substantial subacute nephrotoxicity in patients with mCRPC treated with Lu-177 PSMA I&T regardless of mean absorbed kidney dose","volume":"50","author":"Dotinga","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","volume":"64","author":"Emmett","year":"2017","journal-title":"Journal of medical radiation sciences"},{"issue":"9","key":"10.1016\/j.apradiso.2024.111527_bib57","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.apradiso.2024.111527_bib59","series-title":"Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P","first-page":"289","article-title":"Radioiodine-labeled meta-iodobenzylguanidine for imaging and treatment of pheochromocytoma\/paraganglioma and neuroblastoma","author":"Fischer","year":"2024"},{"key":"10.1016\/j.apradiso.2024.111527_bib60","series-title":"Therapeutic Nuclear Medicine","first-page":"423","article-title":"Radiolabelled bisphosphonates for bone pain palliation","author":"Fischer","year":"2014"},{"issue":"9","key":"10.1016\/j.apradiso.2024.111527_bib61","first-page":"1519","article-title":"Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome","volume":"37","author":"Fj\u00e4lling","year":"1996","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib62","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.nimb.2019.04.022","article-title":"Very high specific activity erbium 169Er production for potential receptor-targeted radiotherapy","volume":"463","author":"Formento-Cavaier","year":"2020","journal-title":"Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. Atoms"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.beem.2007.01.007","article-title":"Peptide receptor radionuclide therapy","volume":"21","author":"Forrer","year":"2007","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.apradiso.2024.111527_bib64","series-title":"Therapeutic Nuclear Medicine","first-page":"781","article-title":"Comparison between \u03b2-emitting isotopes and \u03b1-emitters regarding their effects on cancer cells","author":"Geerlings","year":"2014"},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib65","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy","volume":"35","author":"Giammarile","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib66","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.semnuclmed.2009.11.002","article-title":"Radioimmunotherapy of lymphoma: bexxar and zevalin","volume":"40","author":"Goldsmith","year":"2010","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib67","series-title":"An Overview of Targeted Radiotherapy. Radiopharmaceutical Chemistry","first-page":"85","author":"Grzmil","year":"2019"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1479-5876-5-15","article-title":"Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio","volume":"5","author":"Gulec","year":"2007","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib69","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3348\/kjr.2023.0656","article-title":"Dosimetric analysis of a phase I study of PSMA-targeting radiopharmaceutical therapy with [177Lu]ludotadipep in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"Ha","year":"2024","journal-title":"Korean J. Radiol."},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib70","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00259-018-3947-x","article-title":"EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides","volume":"45","author":"Handkiewicz-Junak","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib71","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12885-022-09329-2","article-title":"The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis","volume":"22","author":"He","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib72","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.juro.2016.02.2969","article-title":"Systemic radioligand therapy with 177Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer","volume":"196","author":"Heck","year":"2016","journal-title":"J. Urol."},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib73","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"\"[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer.\"","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.apradiso.2024.111527_bib74","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera(\u00ae): the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.123.265448","article-title":"Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy","volume":"65","author":"Herrmann","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101993","article-title":"Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer","volume":"60","author":"Higano","year":"2023","journal-title":"Eclinicalmedicine"},{"key":"10.1016\/j.apradiso.2024.111527_bib77","first-page":"293","article-title":"Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer","volume":"24","author":"Ho","year":"1997","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib78","series-title":"Liver Radioembolization with 90Y Microspheres","first-page":"171","article-title":"Complications and side effects","author":"Hoffmann","year":"2014"},{"issue":"17","key":"10.1016\/j.apradiso.2024.111527_bib79","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.apradiso.2024.111527_bib80","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"Institute","year":"2017"},{"issue":"22 Pt 1","key":"10.1016\/j.apradiso.2024.111527_bib81","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","article-title":"Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial","volume":"13","author":"Iten","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib82","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.24272","article-title":"[90Yttrium\u2010DOTA]\u2010TOC response is associated with survival benefit in iodine\u2010refractory thyroid cancer: long\u2010term results of a phase 2 clinical trial","volume":"115","author":"Iten","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.apradiso.2024.111527_bib83","series-title":"\u201cBexxar\u201d). Therapeutic Nuclear Medicine","first-page":"505","article-title":"Non-hodgkin lymphoma: radioimmunotherapy using iodine-131 labeled murine anti-CD20 antibodies (131I-tositumomab and tositumomab","author":"Jacene","year":"2014"},{"issue":"8","key":"10.1016\/j.apradiso.2024.111527_bib84","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jvir.2008.05.013","article-title":"Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases","volume":"19","author":"Jakobs","year":"2008","journal-title":"J. Vasc. Intervent. Radiol."},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib85","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jvir.2008.01.009","article-title":"Radioembolization in patients with hepatic metastases from breast cancer","volume":"19","author":"Jakobs","year":"2008","journal-title":"J. Vasc. Intervent. Radiol."},{"issue":"12","key":"10.1016\/j.apradiso.2024.111527_bib86","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3390\/ph16121679","article-title":"Targeted alpha therapy: all we need to know about 225Ac's physical characteristics and production as a potential theranostic radionuclide","volume":"16","author":"Jalloul","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib87","first-page":"617","article-title":"New advances in peptide receptor radionuclide therapy","volume":"43","author":"Jong","year":"2002","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.apradiso.2024.111527_bib88","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000209849","article-title":"Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study","volume":"79","author":"Kalinowski","year":"2009","journal-title":"Digestion"},{"issue":"4","key":"10.1016\/j.apradiso.2024.111527_bib89","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1677\/erc.1.01116","article-title":"Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues","volume":"12","author":"Kaltsas","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib90","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-0038-1625120","article-title":"Serious complications after radiosynoviorthesis. Survey on frequency and treatment modalities","volume":"45","author":"Kampen","year":"2006","journal-title":"Nuklearmedizin"},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib91","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00259-021-05541-7","article-title":"The EANM guideline for radiosynoviorthesis","volume":"49","author":"Kampen","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.apradiso.2024.111527_bib92","series-title":"Resistance to Ibritumomab in Lymphoma","first-page":"79","article-title":"Characteristics of ibritumomab as radionuclide therapy agent","author":"Kawashima","year":"2018"},{"issue":"684","key":"10.1016\/j.apradiso.2024.111527_bib93","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1259\/0007-1285-57-684-1091","article-title":"Adverse reactions to radiopharmaceuticals. United Kingdom 1977-1983","volume":"57","author":"Keeling","year":"1984","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.apradiso.2024.111527_bib94","series-title":"Therapeutic Nuclear Medicine","first-page":"385","article-title":"Radioembolization (Yttrium-90 microspheres) for metastatic hepatic malignancies","author":"Kennedy","year":"2014"},{"issue":"3","key":"10.1016\/j.apradiso.2024.111527_bib95","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib96","first-page":"189","article-title":"Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: a decade of experience","volume":"31","author":"Kesavan","year":"2016","journal-title":"Cancer Biother. Rad."},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-13-2665","article-title":"Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary","volume":"20","author":"Kluetz","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.apradiso.2024.111527_bib98","series-title":"Therapeutic Nuclear Medicine","first-page":"51","article-title":"Rhenium-188 generator-based radiopharmaceuticals for therapy","author":"Knapp","year":"2014"},{"issue":"13","key":"10.1016\/j.apradiso.2024.111527_bib99","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/cncr.29275","article-title":"Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis","volume":"121","author":"Kokabi","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.apradiso.2024.111527_bib100","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib101","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib102","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.apradiso.2024.111527_bib103","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/0972-3919.178252","article-title":"Pharmacovigilance in radiopharmaceuticals","volume":"31","author":"Kumar","year":"2016","journal-title":"Indian J. Nucl. Med."},{"issue":"13","key":"10.1016\/j.apradiso.2024.111527_bib105","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib106","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study","volume":"49","author":"Lam","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"8","key":"10.1016\/j.apradiso.2024.111527_bib107","first-page":"1326","article-title":"188Re-HDD\/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis","volume":"46","author":"Lambert","year":"2005","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib108","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1060028014558153","article-title":"Adverse reactions to radiopharmaceuticals in France: analysis of the national pharmacovigilance Database","volume":"49","author":"Laroche","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.apradiso.2024.111527_bib109","series-title":"Therapeutic Nuclear Medicine","first-page":"269","article-title":"Maximal safe dose method of I-131 in the management of recurrent\/metastatic differentiated thyroid carcinoma","author":"Lee","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib110","series-title":"Therapeutic Nuclear Medicine","first-page":"151","article-title":"Inorganic radionuclides for nuclear medicine therapy","author":"Lee","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib111","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.2147\/OTT.S92473","article-title":"Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.apradiso.2024.111527_bib112","series-title":"Therapeutic Nuclear Medicine","first-page":"571","article-title":"I-131 meta iodobenzylguanidine therapy","author":"Lewington","year":"2014"},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib113","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2516.2004.00913.x","article-title":"Radiation synovectomy by 188Re\u2010Sulfide in haemophilic synovitis","volume":"10","author":"Li","year":"2004","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.apradiso.2024.111527_bib114","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MNM.0b013e32825a6adc","article-title":"A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases","volume":"28","author":"Liepe","year":"2007","journal-title":"Nucl. Med. Commun."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib115","first-page":"953","article-title":"Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases","volume":"44","author":"Liepe","year":"2003","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.apradiso.2024.111527_bib116","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bjc.6601158","article-title":"Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases","volume":"89","author":"Liepe","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.apradiso.2024.111527_bib117","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-05-0172","article-title":"Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab","volume":"11","author":"Lind\u00e9n","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.apradiso.2024.111527_bib118","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4376720","article-title":"Short-term side effects after radioiodine treatment in patients with differentiated thyroid cancer","volume":"2016","author":"Lu","year":"2016","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.apradiso.2024.111527_bib119","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"417","article-title":"Radioimmunotherapy of lymphomas","author":"Luminari","year":"2018"},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib120","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","article-title":"Guidelines for radioiodine therapy of differentiated thyroid cancer","volume":"35","author":"Luster","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"12","key":"10.1016\/j.apradiso.2024.111527_bib121","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.7150\/thno.13348","article-title":"PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status","volume":"5","author":"L\u00fctje","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.apradiso.2024.111527_bib122","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"19","article-title":"Radiopharmaceuticals for therapy of thyroid diseases","author":"Marzo","year":"2018"},{"issue":"4","key":"10.1016\/j.apradiso.2024.111527_bib123","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/ijnm.IJNM_103_18","article-title":"The global perspective of pharmacovigilance in nuclear medicine practice","volume":"33","author":"Meher","year":"2018","journal-title":"Indian J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib124","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/pbc.21391","article-title":"Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy","volume":"50","author":"Modak","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.apradiso.2024.111527_bib125","series-title":"Therapeutic Nuclear Medicine","first-page":"459","article-title":"Radionuclide therapy of inflammatory joint diseases (radiation synovectomy, radiosynoviorthesis)","author":"M\u00f6dder","year":"2014"},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib126","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2516.1999.00287.x","article-title":"A retrospective study on chemical and radioactive synovectomy in severe haemophilia patients with recurrent haemarthrosis","volume":"5","author":"Molho","year":"1999","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib127","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/10428190601059720","article-title":"Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement","volume":"48","author":"Mones","year":"2007","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.apradiso.2024.111527_bib128","first-page":"200","article-title":"An overview of targeted alpha therapy with 225actinium and 213bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr. Rad."},{"issue":"32","key":"10.1016\/j.apradiso.2024.111527_bib129","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90\u2013ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib130","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.brachy.2023.06.228","article-title":"Actinium-225 targeted agents: where are we now?","volume":"22","author":"Mourtada","year":"2023","journal-title":"Brachytherapy"},{"issue":"12","key":"10.1016\/j.apradiso.2024.111527_bib131","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with \u03b1-emitting radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.apradiso.2024.111527_bib132","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib133","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","article-title":"A randomized, dose\u2013response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer","volume":"48","author":"Nilsson","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib134","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clgc.2012.07.002","article-title":"Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases","volume":"11","author":"Nilsson","year":"2013","journal-title":"Clin. Genitourin. Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.apradiso.2024.111527_bib135","first-page":"2548","article-title":"Tandem therapy versus single agent 177Lu-PSMA and 225Ac-PSMA therapy of advanced stage metastatic castration resistant prostate carcinoma: clinical trial from Azerbaijan","volume":"63","author":"Novruzov","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.apradiso.2024.111527_bib136","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.bjc.6600348","article-title":"High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone","volume":"86","author":"O'Sullivan","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib137","first-page":"21","article-title":"Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases","volume":"1","author":"Olea","year":"2002","journal-title":"World J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib138","series-title":"Safety of Medicines: a Guide to Detecting and Reporting Adverse Drug Reactions: Why Health Professionals Need to Take Action","author":"Organization","year":"2002"},{"key":"10.1016\/j.apradiso.2024.111527_bib139","series-title":"Nuclear Medicine Textbook: Methodology and Clinical Applications","first-page":"99","article-title":"Radiopharmaceuticals for therapy","author":"Orsini","year":"2019"},{"key":"10.1016\/j.apradiso.2024.111527_bib140","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib141","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00296-008-0571-2","article-title":"Treatment of skin necrosis after radiation synovectomy with yttrium-90: a case report","volume":"28","author":"Ozturk","year":"2008","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.apradiso.2024.111527_bib142","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib143","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"345","article-title":"Radiopharmaceuticals for bone metastases","author":"Pagano","year":"2018"},{"key":"10.1016\/j.apradiso.2024.111527_bib144","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s002590050017","article-title":"Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases","volume":"27","author":"Palmedo","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib145","series-title":"Nuclear Medicine Therapy: Side Effects and Complications","first-page":"85","article-title":"Radiometabolic therapy of bone metastases","author":"Paone","year":"2019"},{"issue":"3","key":"10.1016\/j.apradiso.2024.111527_bib146","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.semnuclmed.2016.02.002","article-title":"131I-metaiodobenzylguanidine theranostics in neuroblastoma: historical perspectives; practical applications","volume":"46","author":"Parisi","year":"2016","journal-title":"Semin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.apradiso.2024.111527_bib147","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib148","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2012.09.008","article-title":"A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer","volume":"63","author":"Parker","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.apradiso.2024.111527_bib149","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"25","article-title":"Radioiodine therapy of hyperthyroidism","author":"Pepe","year":"2018"},{"issue":"3","key":"10.1016\/j.apradiso.2024.111527_bib150","first-page":"142","article-title":"Adverse reactions to radiopharmaceuticals","volume":"45","author":"P\u00e9rez-Iruela","year":"2021","journal-title":"Farm. Hosp."},{"issue":"9","key":"10.1016\/j.apradiso.2024.111527_bib151","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/1097-0142(19951101)76:9<1662::AID-CNCR2820760924>3.0.CO;2-V","article-title":"Primary hypothyroidism as a consequence of 131I\u2010metaiodobenzylguanidine treatment for children with neuroblastoma","volume":"76","author":"Picco","year":"1995","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib152","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","article-title":"EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib153","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/pbc.22767","article-title":"Thyroid and hepatic function after high\u2010dose 131I\u2010metaiodobenzylguanidine (131I\u2010MIBG) therapy for neuroblastoma","volume":"56","author":"Quach","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.apradiso.2024.111527_bib154","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00270-018-2133-7","article-title":"Holmium-166 radioembolization in hepatocellular carcinoma: feasibility and safety of a new treatment option in clinical practice","volume":"42","author":"Radosa","year":"2019","journal-title":"Cardiovasc. Intervent. Radiol."},{"issue":"9","key":"10.1016\/j.apradiso.2024.111527_bib155","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.116.173757","article-title":"Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis","volume":"57","author":"Rahbar","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib156","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib157","first-page":"S378","article-title":"Investigation on dose-toxicity and dose-response relationship in neuroendocrine liver metastases treated with holmium-166 radioembolization","volume":"50","author":"Ramdhani","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.apradiso.2024.111527_bib158","series-title":"Ablation Therapy with Radioiodine in Adults and Children with Differentiated Thyroid Cancer. Therapeutic Nuclear Medicine","first-page":"245","author":"Reiners","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib159","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fonc.2014.00198","article-title":"Side effects of yttrium-90 radioembolization","volume":"4","author":"Riaz","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.apradiso.2024.111527_bib160","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"127","article-title":"HCC radioembolization with yttrium-90 polymer beads (SIR-Spheres)","author":"Rodari","year":"2018"},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib161","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cncr.11518","article-title":"High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma","volume":"98","author":"Rose","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.apradiso.2024.111527_bib162","series-title":"Physics and Radiobiology of Nuclear Medicine","first-page":"263","article-title":"Radiation biology","author":"Saha","year":"2013"},{"key":"10.1016\/j.apradiso.2024.111527_bib163","series-title":"Radioactive Decay. Fundamentals of Nuclear Pharmacy","first-page":"11","author":"Saha","year":"2018"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib164","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.apradiso.2024.111527_bib165","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cncr.23339","article-title":"Liver disease induced by radioembolization of liver tumors: description and possible risk factors","volume":"112","author":"Sangro","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.apradiso.2024.111527_bib166","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib167","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib168","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2967\/jnumed.119.229229","article-title":"Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy","volume":"61","author":"Sathekge","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib169","series-title":"Nuclear Medicine Therapy: Side Effects and Complications","first-page":"101","article-title":"Selective internal radiotherapy (SIRT) of primary hepatic carcinoma and liver metastases","author":"Schaefer","year":"2019"},{"key":"10.1016\/j.apradiso.2024.111527_bib170","series-title":"Therapeutic Nuclear Medicine","first-page":"301","article-title":"Follow-up of thyroid cancer patients and treatment of distant metastases","author":"Schlumberger","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib171","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"165","article-title":"Radioembolization of hepatic metastases with 90Y-microspheres: indications and procedure","author":"Sciuto","year":"2018"},{"key":"10.1016\/j.apradiso.2024.111527_bib172","series-title":"Therapeutic Nuclear Medicine","first-page":"557","article-title":"Targeted alpha particle therapy of peritoneal carcinomas","author":"Seidl","year":"2014"},{"key":"10.1016\/j.apradiso.2024.111527_bib173","series-title":"Radiopharmaceutical Chemistry.","first-page":"619","article-title":"The clinical translation process in the United States","author":"Sequeira","year":"2019"},{"key":"10.1016\/j.apradiso.2024.111527_bib174","series-title":"Clinical Applications of Nuclear Medicine Targeted Therapy","first-page":"59","article-title":"Radioiodine therapy of thyroid cancer","author":"Seregni","year":"2018"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib175","first-page":"2","article-title":"The sodium-iodine symporter and the proton-pump inhibitors in - related to the side effects of- the treatment of thyroid cancer with iodine-131","volume":"10","author":"Sfakianakis","year":"2007","journal-title":"Hellenic J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib176","first-page":"S325","article-title":"Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of 225Ac\/177Lu-PSMA-therapy","volume":"50","author":"Sheikh","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"24","key":"10.1016\/j.apradiso.2024.111527_bib177","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.3390\/cancers14246225","article-title":"A single dose of novel PSMA-targeting radiopharmaceutical agent [177Lu]ludotadipep for patients with metastatic castration-resistant prostate cancer: phase I clinical trial","volume":"14","author":"Shin","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.apradiso.2024.111527_bib178","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4103\/wjnm.WJNM_68_17","article-title":"Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies","volume":"17","author":"Shinto","year":"2018","journal-title":"World J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.apradiso.2024.111527_bib179","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2967\/jnumed.114.138057","article-title":"Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011","volume":"55","author":"Silberstein","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib180","first-page":"185","article-title":"Prevalence of adverse reactions in nuclear medicine. Pharmacopeia committee of the society of nuclear medicine","volume":"37","author":"Silberstein","year":"1996","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib181","first-page":"109","article-title":"Adverse reactions to radiopharmaceuticals ARRP: particularly to technetium radiopharmaceuticals","volume":"33","author":"Silindir","year":"2008","journal-title":"Fabad J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib182","first-page":"446","article-title":"Targeted alpha therapy and nanocarrier approach","volume":"35","author":"Silindir-Gunay","year":"2020","journal-title":"Cancer Biother. Rad."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib183","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ctrv.2003.07.006","article-title":"Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues","volume":"30","author":"Silverman","year":"2004","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib184","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"8","key":"10.1016\/j.apradiso.2024.111527_bib185","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1093\/ndt\/gfp148","article-title":"Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy","volume":"24","author":"Skalli","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib186","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(12)70334-0","article-title":"Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study","volume":"13","author":"Smits","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.apradiso.2024.111527_bib187","series-title":"Therapeutic Nuclear Medicine","first-page":"11","article-title":"Therapeutic radionuclides: production, physical characteristics, and applications","author":"Srivastava","year":"2014"},{"issue":"1","key":"10.1016\/j.apradiso.2024.111527_bib188","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.apradiso.2024.111527_bib189","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","article-title":"Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations","volume":"51","author":"Strigari","year":"2010","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib190","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00259-003-1363-2","article-title":"Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma","volume":"31","author":"Sundram","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"6","key":"10.1016\/j.apradiso.2024.111527_bib191","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","article-title":"Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment","volume":"42","author":"Svensson","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.apradiso.2024.111527_bib192","first-page":"S651","article-title":"The tyr phenomena: hypo-calcemic response in high volume treatment responders to 177lutetium PSMA therapy","volume":"50","author":"Swiha","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"10","key":"10.1016\/j.apradiso.2024.111527_bib193","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2967\/jnumed.115.155762","article-title":"Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases","volume":"56","author":"Thapa","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib194","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s002590050351","article-title":"Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China","volume":"26","author":"Tian","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2024.111527_bib195","first-page":"151","article-title":"Evaluation of nephrotoxicity of extended Lu177-PSMA in patients with metastatic castration-resistant prostate cancer","volume":"50","author":"Topal","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib196","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin. Nucl. Med."},{"issue":"1 Suppl. l","key":"10.1016\/j.apradiso.2024.111527_bib197","first-page":"83","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"Journal of nuclear medicine"},{"key":"10.1016\/j.apradiso.2024.111527_bib198","first-page":"1","article-title":"Visual deficit possibly caused by lutetium-177 PSMA treatment","volume":"2018","author":"van Kalmthout","year":"2018","journal-title":"BMJ Case Rep."},{"issue":"7","key":"10.1016\/j.apradiso.2024.111527_bib199","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.52.7.548","article-title":"Long term follow up of radiosynovectomy with yttrium-90 silicate in haemophilic haemarthrosis","volume":"52","author":"van Kasteren","year":"1993","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.11523","article-title":"Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma","volume":"98","author":"van Santen","year":"2003","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.apradiso.2024.111527_bib201","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.ejca.2005.02.036","article-title":"Endocrine late effects from multi-modality treatment of neuroblastoma","volume":"41","author":"Van Santen","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.apradiso.2024.111527_bib202","series-title":"Nuclear Medicine Therapy: Side Effects and Complications","first-page":"35","article-title":"Radioiodine therapy of thyroid cancer","author":"Verburg","year":"2019"},{"issue":"7","key":"10.1016\/j.apradiso.2024.111527_bib203","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib204","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","article-title":"EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds","volume":"49","author":"Weber","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.apradiso.2024.111527_bib205","first-page":"171","article-title":"Radioligand therapy with [177Lu]Lu-PSMA I&T in the elderly - safety, efficacy and prognosticators of survival","volume":"50","author":"Weber","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"8","key":"10.1016\/j.apradiso.2024.111527_bib206","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study","volume":"55","author":"Wild","year":"2014","journal-title":"Journal of nuclear medicine"},{"issue":"7","key":"10.1016\/j.apradiso.2024.111527_bib207","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.apradiso.2024.111527_bib208","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.apradiso.2024.111527_bib209","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib210","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"11","key":"10.1016\/j.apradiso.2024.111527_bib211","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jvir.2007.07.016","article-title":"Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma","volume":"18","author":"Young","year":"2007","journal-title":"J. Vasc. Intervent. Radiol."},{"issue":"2","key":"10.1016\/j.apradiso.2024.111527_bib212","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/RLU.0b013e318279bf4d","article-title":"Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study","volume":"38","author":"Yuan","year":"2013","journal-title":"Clin. Nucl. Med."},{"issue":"5","key":"10.1016\/j.apradiso.2024.111527_bib213","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.apradiso.2024.111527_bib214","series-title":"Therapeutic Nuclear Medicine","first-page":"173","article-title":"Economic and industrial considerations for marketing of therapeutic radiopharmaceuticals","author":"Zimmermann","year":"2014"}],"container-title":["Applied Radiation and Isotopes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804324003555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804324003555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:01:25Z","timestamp":1730365285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969804324003555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":213,"alternative-id":["S0969804324003555"],"URL":"https:\/\/doi.org\/10.1016\/j.apradiso.2024.111527","relation":{},"ISSN":["0969-8043"],"issn-type":[{"value":"0969-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse reactions to therapeutic radiopharmaceuticals","name":"articletitle","label":"Article Title"},{"value":"Applied Radiation and Isotopes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apradiso.2024.111527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111527"}}